Veracyte, Inc.

Valuation Analysis

About the Company

Veracyte, Inc. en bref

Veracyte, Inc. (VCYT) is currently trading at 46,80 € with a market capitalization of 3,7 Md €. The trailing P/E ratio stands at 49.66x, with a forward P/E of 28.21x. The 52-week range spans from 19,73 € to 46,96 €; the current price is 0.3% below the yearly high. Year-over-year revenue growth stands at +21.5%. The net profit margin stands at 16.25%.

💰 Dividende

Veracyte, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

10 analystes évaluent Veracyte, Inc. (VCYT) au consensus : Acheter. L'objectif de cours moyen est de 42,85 €, soit un potentiel de -8.45% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 32,29 € à 49,74 €.

Veracyte, Inc. : la thèse d'investissement en détail

Veracyte, Inc. (VCYT) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 21.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 288.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 72.91%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

With a beta near 1.98, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 10.9% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 35.15x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 28.21x is meaningfully below the trailing 49.66x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 99.4% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (10.9%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Veracyte, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.